Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$33M
- +11.4% YoY · +27.5% QoQ
- EPS (diluted)
- −$0.42
- +6.7% YoY · +26.3% QoQ
Source: XBRL data from the Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 10-Q on SEC EDGAR. USD.
Atea Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved products or product sales
- Net loss $32.9M vs $37.2M YoY; operating loss $35.1M vs $41.3M
- HCV external R&D $17.9M vs $24.3M; HEV external R&D $2.9M vs $0
- Cash, equivalents and marketable securities $219.5M; operating cash use $83.5M for six months
- C-FORWARD results expected early Q1 2027; FDA NDA submission targeted Q2 2027
Risk Factors
- HCV lead program depends on C-FORWARD Phase 3 success, with topline results expected early Q1 2027
- Regulatory approval risk includes potential FDA requirements for additional clinical trials or studies before HCV commercialization
- Liquidity risk: $78.4 million net loss in six months ended June 30, 2026, with no product revenue
- Operational risk: COVID-19 development discontinued after SUNRISE-3 failed its primary endpoint in 2,221 patients
- Financial concentration: majority of cash held at U.S. banks, potentially exceeding the FDIC’s $250,000 insurance limit
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Atea Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.